ProQR Therapeutics (PRQR) Total Debt (2016 - 2026)

ProQR Therapeutics (PRQR) has reported Total Debt for 11 consecutive years, with $5.6 million the latest figure, recorded in Q1 2026.

• Quarterly Total Debt rose 6.23% year-over-year to $5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.6 million (up 6.23% YoY) and the FY2025 annual result came in at $5.5 million, up 6.33% from the prior year.
• Total Debt climbed to $5.6 million in Q1 2026 per PRQR's latest filing, from $5.5 million in the prior quarter.
• Over the last five years, Total Debt for PRQR reached as high as $51.2 million in Q2 2022 and fell as low as $4.9 million in Q4 2023.
• A 5-year average of $11.2 million and a median of $5.5 million in 2025 frame the typical range for Total Debt.
• Annual changes were most pronounced in 2022 — Total Debt surged 142.75% — and 2023, when it plunged 85.56%.
• Year by year, Total Debt stood at $7.7 million in 2022, then sank by 36.61% to $4.9 million in 2023, then increased by 6.76% to $5.2 million in 2024, then advanced by 6.33% to $5.5 million in 2025, then gained by 1.5% to $5.6 million in 2026.
• According to Business Quant data, Total Debt over the past three periods registered $5.6 million, $5.5 million, and $5.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.